Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,400 shares of the company on 12-31-2024. This trade was reported by Quiver Quantitative using data from a ...

Greenwich LifeSciences Inc. (NASDAQ: GLSI) stock is trading higher on Monday, with a session volume of 2.804 million compared to the average volume of 81.85 thousand, as per data from Benzinga Pro.

The average one-year price target for Greenwich LifeSciences (NasdaqCM:GLSI) has been revised to $48.45 / share. This is an ...

Greenwich LifeSciences (NASDAQ:GLSI) just reported results for the first quarter of 2024. Greenwich LifeSciences reported earnings per share of -19 cents. This was above the analyst estimate for EPS ...

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) stock rose Friday, even as the company disclosed no new announcements to explain the move. The stock action follows a corporate update earlier this week ...

Greenwich LifeSciences (NASDAQ:GLSI) just reported results for the second quarter of 2024. Greenwich LifeSciences reported earnings per share of -20 cents. The company did not report any revenue for ...

The company highlighted an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial. The company noted that the latest observation trended similarly to its ...

Greenwich LifeSciences, Inc. is a late-stage biotech company focusing on developing an immunotherapy treatment for breast cancer. Their pipeline includes one drug, GLSI-100, currently in a phase 3 ...